Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF in children at high risk of RSV disease
NCT07839871Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- Apr 2031
- Countries
- 2
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07839871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839871.